DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-297/S-022

SmithKline Beecham Corporation d/b/a GlaxoSmithKline
Attention: Ms. Catherine K. Clark
One Franklin Plaza
200 N. 16th Street
Philadelphia, PA 19102

Dear Ms. Clark:

Please refer to your supplemental new drug application dated September 1, 2006 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Coreg (carvedilol) 3.125, 6.25, 12.5 and 25 mg Tablets.

We acknowledge receipt of your submissions dated October 10, 13, 26, and 27 and November 16, 2006 and January 18 and February 22, 2007.

This supplemental new drug application provides for language to incorporate the results of Study 321, a multicenter, placebo-controlled, 8-month study of the effect of twice daily carvedilol in children with congestive heart failure and Study 396, a multicenter, open-label extension study to evaluate the safety of twice daily oral carvedilol in pediatric subjects with chronic heart failure in the approved package insert and reformat the package insert to conform with the Physician Labeling Rule.

We have completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert and patient package insert).

Submit content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/oc/datacouncil/spl.html, that is identical in content to the enclosed labeling. Upon receipt and verification, we will transmit that version to the National Library of Medicine for posting on the DailyMed website.

In addition, within 21 days of the date of this letter, amend any pending applications for this NDA with content of labeling in SPL format to include the changes approved in this application.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We note that you have fulfilled the pediatric study requirement for this application.

We remind you of your postmarketing study commitment in your submission dated February 22, 2007. This commitment is listed below.

1. To search the existing databases for hypertension, PMI-LVD, and heart failure and determine what happens in hepatically impaired patients when they are initiated on doses above 3.125 mg to determine if the following dosing recommendation for patients with mild to moderate hepatic insufficiency: "For patients with mild to moderate hepatic impairment, start dosing at 3.125 mg twice daily." is justified. You committed to providing the results of the search to us by October 1, 2007.

Submit all study final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies, number of patients entered into each study. All submissions, including supplements, relating to this postmarketing study commitment must be prominently labeled "**Postmarketing Study Commitment Final Report**", or "**Postmarketing Study Commitment Correspondence**."

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call:

Ms. Melissa Robb
Regulatory Health Project Manager
(301) 796-1138

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure: Agreed-upon labeling text

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Norman Stockbridge

2/23/2007 02:46:27 PM